Articles with public access mandates - Huzaifa I Adamali - National Institute for Health Research, UKLearn more
NoteFor this mandate, articles should be available from specific locations.
Not available based on mandate: 10
Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial
D Visca, L Mori, V Tsipouri, S Fleming, A Firouzi, M Bonini, MJ Pavitt, ...
The Lancet Respiratory Medicine 6 (10), 759-770, 2018
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
TM Maher, S Stowasser, Y Nishioka, ES White, V Cottin, I Noth, M Selman, ...
The Lancet respiratory medicine 7 (9), 771-779, 2019
No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone
L Richeldi, S Fletcher, H Adamali, N Chaudhuri, S Wiebe, S Wind, K Hohl, ...
European Respiratory Journal 53 (1), 2019
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open …
O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ...
The Lancet 401 (10387), 1499-1507, 2023
Duration of benefit following completion of pulmonary rehabilitation in interstitial lung disease—an observational study
C Sharp, M McCabe, MJ Hussain, JW Dodd, H Lamb, H Adamali, ...
QJM: An International Journal of Medicine 110 (1), 17-22, 2017
Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial
JA Whitty, J Rankin, D Visca, V Tsipouri, L Mori, L Spencer, H Adamali, ...
European Respiratory Journal 55 (2), 2020
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised …
SN Faust, R Haynes, CE Jones, N Staplin, E Whittaker, T Jaki, E Juszczak, ...
The Lancet Child & Adolescent Health 8 (3), 190-200, 2024
Long COVID research: an update from the PHOSP-COVID Scientific Summit
CE Brightling, RA Evans, A Singapuri, N Smith, LV Wain, CE Brightling, ...
The Lancet Respiratory Medicine 11 (11), e93-e94, 2023
Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK
M Taquet, Z Skorniewska, T De Deyn, A Hampshire, WR Trender, ...
The Lancet Psychiatry, 2024
What role for asbestos in idiopathic pulmonary fibrosis? Findings from the IPF job exposures study
CJ Reynolds, R Sisodia, C Barber, C Minelli, SD Matteis, M Moffatt, ...
medRxiv, 2021.03. 09.21253224, 2021
Available based on mandate: 21
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group
Lancet (London, England) 397 (10285), 1637, 2021
Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort
DT Arnold, FW Hamilton, A Milne, AJ Morley, J Viner, M Attwood, A Noel, ...
Thorax 76 (4), 399-401, 2021
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
RA Evans, H McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ...
The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ...
Medrxiv, 2021.06. 15.21258542, 2021
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study
RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ...
The Lancet Respiratory Medicine 10 (8), 761-775, 2022
Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized …
GD Perkins, C Ji, BA Connolly, K Couper, R Lall, JK Baillie, JM Bradley, ...
Jama 327 (6), 546-558, 2022
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ...
The Lancet 400 (10349), 359-368, 2022
Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study
TM Drake, AB Docherty, EM Harrison, JK Quint, H Adamali, S Agnew, ...
American journal of respiratory and critical care medicine 202 (12), 1656-1665, 2020
Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
AM Russell, H Adamali, PL Molyneaux, PT Lukey, RP Marshall, ...
American journal of respiratory and critical care medicine 194 (8), 989-997, 2016
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ...
EBioMedicine 87, 2023
Publication and funding information is determined automatically by a computer program